404 related articles for article (PubMed ID: 33299899)
1. Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.
Dos Anjos F; Simões JLB; Assmann CE; Carvalho FB; Bagatini MD
J Immunol Res; 2020; 2020():8632048. PubMed ID: 33299899
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.
Korb VG; Schultz IC; Beckenkamp LR; Wink MR
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175571
[TBL] [Abstract][Full Text] [Related]
3. Targeting adenosinergic pathway and adenosine A
Abouelkhair MA
Med Hypotheses; 2020 Nov; 144():110012. PubMed ID: 32590324
[TBL] [Abstract][Full Text] [Related]
4. Possible role of purinergic signaling in COVID-19.
Franciosi MLM; Lima MDM; Schetinger MRC; Cardoso AM
Mol Cell Biochem; 2021 Aug; 476(8):2891-2898. PubMed ID: 33740184
[TBL] [Abstract][Full Text] [Related]
5. Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.
Leão Batista Simões J; Fornari Basso H; Cristine Kosvoski G; Gavioli J; Marafon F; Elias Assmann C; Barbosa Carvalho F; Dulce Bagatini M
Int Immunopharmacol; 2021 Nov; 100():108150. PubMed ID: 34537482
[TBL] [Abstract][Full Text] [Related]
6. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
7. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
8. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
9. Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.
Shafaghat Z; Ghomi AK; Khorramdelazad H; Safari E
Inflammopharmacology; 2023 Dec; 31(6):3005-3020. PubMed ID: 37805959
[TBL] [Abstract][Full Text] [Related]
10. Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases.
Andrejew R; Glaser T; Oliveira-Giacomelli Á; Ribeiro D; Godoy M; Granato A; Ulrich H
Adv Exp Med Biol; 2019; 1201():275-353. PubMed ID: 31898792
[TBL] [Abstract][Full Text] [Related]
11. Targeting purinergic receptors to attenuate inflammation of dry eye.
Wang JN; Fan H; Song JT
Purinergic Signal; 2023 Mar; 19(1):199-206. PubMed ID: 35218451
[TBL] [Abstract][Full Text] [Related]
12. Agonists and Antagonists for Purinergic Receptors.
Müller CE; Baqi Y; Namasivayam V
Methods Mol Biol; 2020; 2041():45-64. PubMed ID: 31646479
[TBL] [Abstract][Full Text] [Related]
13. Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.
Nadeali Z; Mohammad-Rezaei F; Aria H; Nikpour P
Life Sci; 2022 May; 297():120482. PubMed ID: 35288174
[TBL] [Abstract][Full Text] [Related]
14. The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2.
Hernandez CA; Eugenin EA
Curr Opin Pharmacol; 2023 Dec; 73():102404. PubMed ID: 37734241
[TBL] [Abstract][Full Text] [Related]
15. Purinergic signaling in diabetes and metabolism.
Jain S; Jacobson KA
Biochem Pharmacol; 2021 May; 187():114393. PubMed ID: 33359363
[TBL] [Abstract][Full Text] [Related]
16. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells.
Yoshida K; Ito M; Matsuoka I
Int Immunopharmacol; 2017 Feb; 43():99-107. PubMed ID: 27988461
[TBL] [Abstract][Full Text] [Related]
17. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.
DiNicolantonio JJ; Barroso-Aranda J
Med Hypotheses; 2020 Oct; 143():110051. PubMed ID: 32650197
[TBL] [Abstract][Full Text] [Related]
18. Purinergic signalling in host innate immune defence against intracellular pathogens.
Coutinho-Silva R; Savio LEB
Biochem Pharmacol; 2021 May; 187():114405. PubMed ID: 33406411
[TBL] [Abstract][Full Text] [Related]
19. Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium.
Bergamin LS; Braganhol E; Figueiró F; Casali EA; Zanin RF; Sévigny J; Battastini AM
J Cell Biochem; 2015 May; 116(5):721-9. PubMed ID: 25546398
[TBL] [Abstract][Full Text] [Related]
20. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science.
Evans PC; Rainger GE; Mason JC; Guzik TJ; Osto E; Stamataki Z; Neil D; Hoefer IE; Fragiadaki M; Waltenberger J; Weber C; Bochaton-Piallat ML; Bäck M
Cardiovasc Res; 2020 Dec; 116(14):2177-2184. PubMed ID: 32750108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
